Therapy Areas: Oncology
Persephone Biosciences Forges Collaboration with Janssen Biotech
21 September 2021 - - US-based microbiome-focused biotechnology company Persephone Biosciences Inc has entered into a collaboration agreement with US-based healthcare company Johnson and Johnson's (NYSE: JNJ) Janssen Biotech, Inc business, the company said.

The agreement was facilitated by Johnson and Johnson Innovation.

Under the collaboration, Persephone will analyze stool samples collected as part of a Janssen oncology clinical trial using Persephone's proprietary stool collection kit, and the company will have exclusive licensing rights to any biomarkers discovered.

Persephone's laboratories are currently located at the Johnson and Johnson Innovation JLABS incubator in San Diego, CA and the company is also part of Blue Knight, a joint initiative between Johnson and Johnson Innovation JLABS and the Biomedical Advanced Research and Development Authority (BARDA) dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements with the aim to prepare for and respond to our rapidly evolving global health environment.

Persephone Biosciences, a Y Combinator company, takes a novel approach to understanding the role of the human microbial ecosystem on therapeutic treatment, diagnostics and disease prevention.

Persephone's technology platform is based on diverse and inclusive, population-scale, observational clinical trials in conjunction with advanced multi-omics analyses and machine learning with the aim to probe the complex interaction between microbes and the immune system.

Persephone develops precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes.


Related Headlines